Imatinib Mesylate is Effective for Patients Not Only with Chronic Myeloid Leukemia, but Also Rheumatoid Arthritis |
Jung, Hyun-Jun
(Department of Internal Medicine, Kyung Hee University School of Medicine, Kyung Hee University Hospital at Gangdong)
Kim, Dae-Ho (Department of Internal Medicine, Kyung Hee University School of Medicine, Kyung Hee University Hospital at Gangdong) Song, Ran (Department of Internal Medicine, Kyung Hee University School of Medicine, Kyung Hee University Hospital at Gangdong) Hong, Seung-Jae (Department of Internal Medicine, Kyung Hee University School of Medicine, Kyung Hee University Medical Center) Yang, Hyung-In (Department of Internal Medicine, Kyung Hee University School of Medicine, Kyung Hee University Hospital at Gangdong) Eo,Wan-Kyu (Department of Internal Medicine, Kyung Hee University School of Medicine, Kyung Hee University Hospital at Gangdong) Lee, Sang-Hoon (Department of Internal Medicine, Kyung Hee University School of Medicine, Kyung Hee University Hospital at Gangdong) |
1 | Miyachi K, Ihara A, Hankins RW, Murai R, Maehiro S, Miyashita H. Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia. Clin Rheumatol 2003;22: 329-332. DOI ScienceOn |
2 | Takeuchi T, Abe T. Tyrosine phosphorylated proteins in synovial cells of rheumatoid arthritis. Int Rev Immunol 1998;17:365-381. DOI |
3 | Eklund KK. Mast cells in the pathogenesis of rheumatic diseases and as potential targets for anti-rheumatic therapy. Immunol Rev 2007;217:38-52. DOI ScienceOn |
4 | Pereira I, Fialho S, Castro G, Zimmermann A. Imatinib mesylate induces clinical remission in rheumatoid arthritis. Joint Bone Spine 2010;77:372-373. DOI ScienceOn |
5 | Jeon HK, Park YE, Kim SI, et al. Efficacy of imatinib mesylate treatment for a patient with rheumatoid arthritis and who developed chronic myelogenous leukemia. J Rheum Dis 2011;18:118-121. DOI |
6 | National Cancer Information Center. Cancer Definition [Internet]. Seoul (KR): National Cancer Information Center, c2012 [cited 2012 Feb 15]. Available from: http://www.cancer.go.kr/ncic/cics_b/ 01/012/1253431_5872.html. |
7 | Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139-145. |
8 | Askling J, Fored CM, Baecklund E, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005;64:1414-1420. DOI ScienceOn |
9 | Thomas E, Brewster DH, Black RJ, Macfarlane GJ. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000;88:497-502. DOI ScienceOn |
10 | Senel S, Kaya E, Aydogdu I, Erkurt MA, Kuku I. Rheumatic diseases and chronic myelogenous leukemia, presentation of four cases and review of the literature. Rheumatol Int 2006;26:857-861. DOI ScienceOn |